A Phase II clinical trial has shown that a two-week course of interferon beta-1b plus lopinavir-ritonavir and ribavirin, started within seven days of showing COVID-19 symptoms, is safe and effective.
List view / Grid view
Filter the results
A Phase IV trial in 86 patients with mild-to-moderate COVID-19 has indicated that lopinavir/ritonavir (LPV/r) and Arbidol do not improve clinical outcomes.
Despite some positive results from clinical trials for COVID-19 treatments, separate tests of the same therapies have not met primary endpoints.
The first regulatory approval for Cabenuva (cabotegravir and rilpivirine) has been granted by Health Canada, in conjunction with use of Vocabria.
A new single-step technique has been developed which could enable the synthesis of water-soluble fullerene compounds for use in pharma.
Researchers have shown that using mobile vans to deliver and dispense HIV drugs in South Africa and Uganda helps to combat the disease.
Researchers report that a patient who underwent stem-cell transplantation and a chemotherapy drug regimen has been cured of HIV.
Using AAV-based technology to deliver mAbs in a Phase I trial, researchers report that participants successfully developed antibodies against HIV.
New research from PhRMA found that in the US, there are almost 600 paediatric medicines in development in over 2,000 clinical trials.
The US NIAID has stopped its HVTN 702 clinical trial for an HIV vaccine after an independent board found that the treatment did not prevent the condition.
A novel formulation for dolutegravir has been developed to improve HIV treatment options for children. Dr Kimberly Smith from ViiV Healthcare discusses the benefits of this new dispersible tablet.
A new report has shown a high level of novelty and diversity for the HIV first-in-class pipeline which targets drug resistance and latency reversal.
The Japanese Ministry of Health, Labour and Welfare (MHLW) has granted marketing approval for Dovato, a treatment for HIV-1 infection.
Drug makers have hiked the price of over 250 drugs in the US so far in 2020, according to new reports.
The investigational broadly neutralising antibody, N6LS, is to be developed by ViiV Healthcare for the treatment and prevention of HIV-1.